ByeAcne/Problem
Post-Acne Dark Spots (PIH) Treatment — Prescription Fading That Works
Post-inflammatory hyperpigmentation from acne can be more persistent than the acne itself. Prescription treatment targets melanin overproduction at the source.
Reviewed by a licensed physician · Updated May 2026
Post-inflammatory hyperpigmentation is the shadow that acne leaves behind — sometimes more visible and longer-lasting than the acne itself, particularly in patients with Fitzpatrick skin types IV through VI. The flat, dark marks are not scars (no structural skin damage has occurred), but they can persist for 6-18 months without treatment, causing ongoing visible skin impairment long after the active acne has resolved.
Prescription treatment accelerates PIH resolution through three complementary mechanisms. Tretinoin dramatically speeds up epidermal cell turnover, bringing pigmented cells to the surface and accelerating their shedding before they can transfer melanin to the layers below. Azelaic acid inhibits tyrosinase activity, reducing the ongoing melanin overproduction that extends the PIH pigment deposit. Prescription hydroquinone provides direct bleaching through melanocyte suppression, particularly valuable for rapid fading of established dark spots.
Sun protection is the fourth element of PIH treatment — and the one patients most commonly underestimate. UV exposure stimulates the very melanocytes you are trying to suppress, counteracting your prescription treatment. Daily broad-spectrum SPF 30-50 is not optional when treating PIH; it is a mandatory co-intervention. Your ByeAcne physician will build sun protection guidance into your complete PIH treatment plan.
How PIH forms — and what actually fades it
PIH is not a scar. When acne heals, inflammation in the dermis signals melanocytes at the dermal-epidermal junction to produce extra melanin. This excess melanin is deposited into surrounding keratinocytes (epidermal PIH, which fades faster) or into the dermis itself via pigment incontinence (dermal PIH, which fades much more slowly). The darker your baseline skin tone, the more reactive your melanocytes are to inflammatory signals, and the darker and longer-lasting the resulting PIH tends to be.
Treatment works through three mechanisms operating in parallel. Cell turnover acceleration (from retinoids) brings the pigmented surface cells to the top of the epidermis faster, where they shed. Tyrosinase inhibition (from azelaic acid, kojic acid, arbutin, or prescription hydroquinone) reduces the ongoing melanin production that would otherwise replenish the pigmented cells. Sun avoidance and sun protection prevent UV-triggered melanocyte activation that would continuously top up the pigment you are trying to fade.
The time course is meaningful. Epidermal PIH responds to treatment within 8–12 weeks. Dermal PIH can take 4–6 months or longer. Marks that have been present for years are slower still. Patience is part of the prescription. Consistent daily use of the regimen over months is the single biggest predictor of visible fading — more important than which specific agents are chosen at the margins.
Treatment options a doctor may consider
- Topical tretinoin (0.025–0.05%)
Accelerates cell turnover and PIH fading. Nightly application. Layered with ceramide moisturizer. Most effective in combination with a tyrosinase inhibitor.
- Azelaic acid 15–20%
Inhibits tyrosinase directly while also treating any residual acne. Twice-daily application. Particularly effective in medium-to-dark skin where hydroquinone tolerance may be limited.
- Prescription hydroquinone 2–4%
Most direct melanocyte suppressant available. Used in cycles of 3–6 months to avoid the rare risk of ochronosis with very long-term use. Often produces the fastest visible fading.
- Kojic acid, arbutin, niacinamide adjuncts
Tyrosinase and melanosome transfer inhibitors available in both prescription compounded formulations and quality OTC serums. Useful as rotation partners during hydroquinone breaks.
- Daily broad-spectrum SPF 30–50 (mineral preferred)
Non-negotiable for PIH treatment. UV exposure counteracts topical pigment suppression one-for-one. Zinc oxide or titanium dioxide sunscreens protect against visible light too, which also contributes to pigment production.
Your specific regimen depends on your medical history, current medications, and intake photos. Only your physician can determine what's appropriate.
Who benefits most from PIH treatment
Patients whose active acne is under control or resolving, but who are left with dark marks that persist months after the original lesions healed. Patients with Fitzpatrick skin types IV–VI where PIH is typically the primary long-term concern after acne clears. Patients who want to prevent future PIH by establishing treatment before their acne fully resolves. Not the right primary focus for patients with active moderate-to-severe inflammatory acne (treat the acne first — PIH treatment without acne control is chasing marks while new ones keep forming), those with raised or atrophic scars (those are structural scars requiring procedural intervention, not topical fading), or patients with melasma that may coexist with PIH but responds to different treatment protocols.